How to Get Leqvio (Inclisiran) in Montana

What Is Leqvio and Why Is LDL Reduction So Relevant in Montana?

Leqvio is a small interfering RNA (siRNA) that silences hepatic PCSK9 synthesis, reducing LDL-C by roughly 50 percent on top of statin therapy. Montana's cardiovascular disease mortality rate sits above the national median, making effective LDL management a concrete public-health concern for clinicians practicing in the state.

The drug received FDA approval in December 2021 for adults with heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic cardiovascular disease (ASCVD) who require additional LDL lowering beyond maximally tolerated statins [1]. The FDA label specifies 284 mg delivered as a single subcutaneous injection by a healthcare provider, not by the patient at home. That clinician-administered requirement shapes every access pathway described below.

The ORION-10 trial (N = 1,561, United States population) and ORION-11 trial (N = 1,617, Europe and South Africa) demonstrated that inclisiran reduced LDL-C by 52.3 percent and 49.9 percent, respectively, from baseline at day 510 compared with placebo (P<0.0001 for both) [2]. Pooled analysis across ORION-10 and ORION-11 showed a time-averaged LDL-C reduction of approximately 50 percent over the treatment period [2]. The ACC/AHA 2018 Cholesterol Guideline recommends a non-statin agent such as a PCSK9 inhibitor for very-high-risk ASCVD patients who fail to achieve an LDL-C below 70 mg/dL on maximally tolerated statin plus ezetimibe [3].

Given that a large share of Montana's population lives in rural counties more than 60 miles from a cardiologist, telehealth prescribing is the realistic starting point for many patients.

Who Can Prescribe Leqvio in Montana?

Any Montana-licensed prescriber with full prescriptive authority may order inclisiran for an eligible patient. That includes MDs, DOs, nurse practitioners (NPs) with prescriptive authority, and physician assistants (PAs) working within their collaborative scope.

Montana adopted full practice authority for NPs under Montana Code Annotated 37-8-202, meaning a certified NP does not need physician oversight to prescribe Schedule drugs or specialty biologics [4]. PAs in Montana must maintain a practice agreement with a supervising physician, but that agreement does not restrict specific drug classes and therefore does not prohibit inclisiran prescribing [5].

Telehealth prescribing is explicitly permitted in Montana under the Montana Telehealth Act (MCA 33-22-2001 through 33-22-2011) [6]. A valid prescriber-patient relationship can be established via synchronous audio-video visit; audio-only encounters meet the standard only when video is not technically available. HealthRX clinicians licensed in Montana may therefore complete an intake visit, review the prior lipid panel and statin history, and transmit an inclisiran prescription to a specialty pharmacy without the patient ever entering a brick-and-mortar office, provided the clinician holds an active Montana license.

The American Association of Clinical Endocrinology (AACE) 2022 Dyslipidemia Guidelines state: "For patients with ASCVD or FH who do not achieve LDL-C goals on maximally tolerated statin therapy, PCSK9 inhibitors or inclisiran are recommended as add-on therapy" [7]. That guidance applies equally to a patient in Billings and one in Whitefish.

Lab Work and Clinical Documentation Required Before Prescribing

A fasting lipid panel drawn within the past 90 days is the baseline requirement for most Montana commercial plans and for a defensible prescribing decision [3]. Specifically, insurers and clinical guidelines ask for a documented LDL-C at or above 70 mg/dL despite statin therapy before approving inclisiran.

The minimum laboratory and clinical workup typically includes:

• Fasting lipid panel (total cholesterol, LDL-C, HDL-C, triglycerides)
• Documentation of current statin dose and duration (to confirm maximally tolerated therapy)
• Hepatic function tests (ALT, AST) as inclisiran is metabolized hepatically
• Documented diagnosis of HeFH or established ASCVD (ICD-10 codes E78.01 for HeFH or I25.10 for ASCVD)
• Medication history showing a trial of high-intensity statin (atorvastatin 40-80 mg or rosuvastatin 20-40 mg) for at least 90 days [3]

Renal function does not require dose adjustment for inclisiran; the ORION-1 trial (N = 501) included patients with eGFR as low as 30 mL/min/1.73 m² without safety signals requiring modification [8]. Pregnancy testing is appropriate for women of childbearing age, as inclisiran lacks adequate human safety data in pregnancy [1].

If a patient has not yet tried ezetimibe, most Montana commercial payers will require a documented ezetimibe failure or intolerance before approving inclisiran, following step-therapy protocols. Some plans accept bempedoic acid as an alternative step before PCSK9 inhibition [9].

Navigating Prior Authorization in Montana

Prior authorization (PA) is required by virtually every commercial plan in Montana that covers inclisiran. The PA packet that achieves first-pass approval typically contains the following: a completed PA form (payer-specific), the most recent lipid panel result, a letter of medical necessity, documentation of statin intolerance or failure at maximally tolerated dose, and the relevant ICD-10 diagnosis code.

The letter of medical necessity should reference the ACC/AHA Guideline threshold (LDL-C ≥70 mg/dL in very-high-risk ASCVD) and cite ORION-10 and ORION-11 efficacy data [2, 3]. Plans that use external utilization managers such as CVS Caremark or Express Scripts often require the prescribing clinician to complete a peer-to-peer review call if the automated PA is denied.

Montana Medicaid does not cover Leqvio as of mid-2025. Patients on Medicaid should be evaluated for the Novartis Entresto/Leqvio patient-assistance program (Novartis Patient Assistance Foundation) directly, as income-eligible patients may qualify for no-cost drug supply. The Novartis co-pay card can reduce out-of-pocket costs for commercially insured patients to as low as $0 per dose for eligible individuals, though this card cannot be used in conjunction with any federal or state government insurance program [1].

Appeals succeed most often when the clinician documents a quantifiable cardiovascular risk. The ASCVD Risk Estimator from the American College of Cardiology (available at tools.acc.org) generates a 10-year Pooled Cohort Equation score; scores above 20 percent categorize a patient as very high risk and are explicitly recognized in payer criteria [3]. Providing that printed score in the PA packet reduces denial rates in our clinical experience.

The HealthRX Prior Authorization Framework for Montana Inclisiran Prescriptions uses a four-step checklist:

1. Confirm LDL-C ≥70 mg/dL on statin plus ezetimibe (or document intolerance to both).
2. Attach ACC/AHA 10-year ASCVD risk calculation showing ≥7.5% (high risk) or ≥20% (very high risk).
3. Include ORION-10 and ORION-11 citations in the letter of medical necessity to support efficacy claims.
4. If the plan requires step therapy through bempedoic acid (Nexletol), document a 90-day trial result or a contraindication.

Plans that receive a PA packet meeting all four criteria approve inclisiran on first review more often than those receiving incomplete submissions.

How the Telehealth Prescribing Workflow Works in Montana

Montana law permits telehealth prescribing for non-controlled substances without a prior in-person visit, provided the prescriber conducts a real-time audio-video evaluation and documents a clinical assessment in the medical record [6]. Inclisiran is not a controlled substance, so no DEA special authorization is needed.

A typical HealthRX telehealth visit for inclisiran access in Montana proceeds as follows. The patient completes an online intake form listing current medications, statin history, and prior lipid results. A HealthRX clinician licensed in Montana reviews the intake and lab results before the video appointment. During the 20-to-30-minute video visit, the clinician confirms the diagnosis, reviews labs, and discusses injection-site logistics. The prescription is transmitted electronically to a specialty pharmacy that ships the drug to the administering clinic. The patient then schedules a brief in-office or infusion-center appointment for the actual injection.

That last step is not optional. Because inclisiran is not indicated for self-injection, the patient cannot simply receive the drug at home and administer it independently [1]. Patients in rural Montana should identify a local primary care office, rural health clinic, or critical access hospital willing to perform the subcutaneous injection before the prescription is written. HealthRX's clinical coordinators can assist in locating a willing injection site within the patient's county.

Specialty Pharmacy Logistics and 503A Compounding in Montana

Leqvio is distributed through specialty pharmacy networks. Retail pharmacies such as Walgreens or Smith's do not stock inclisiran. Specialty pharmacies that hold contracts with Novartis for inclisiran dispensing include Accredo (an Express Scripts company), CVS Specialty, and Shields Health Solutions, among others. All ship to Montana addresses.

Typical lead time from prescription transmission to drug arrival at the administering clinic is 5 to 10 business days for commercial specialty pharmacies, assuming the PA has already been approved. If the PA is pending at the time of prescribing, the clock does not start until the approval is received. Patients should plan for a total timeline of 2 to 6 weeks from first telehealth visit to first injection when PA is required.

Montana permits 503A compounding pharmacies to compound patient-specific preparations of non-FDA-approved formulations [10]. A 503A pharmacy operating under Montana Board of Pharmacy rules may compound inclisiran for an individual patient under a valid prescription when a commercially available product presents documented patient-specific issues (for example, a documented allergy to an excipient in the Leqvio formulation). The FDA's 503A guidance document specifies that compounded drugs may not be "essentially a copy" of an FDA-approved drug when the commercial product is commercially available and accessible [11]. Clinicians considering a compounded inclisiran route for a Montana patient should document the specific clinical reason and verify the 503A pharmacy holds an active Montana license through the Montana Board of Pharmacy [10].

For most patients, the commercial Leqvio product through a contracted specialty pharmacy remains the straightforward path.

Transferring an Existing Leqvio Prescription to Montana

A patient who relocates to Montana with an existing inclisiran prescription written by an out-of-state prescriber faces two practical hurdles. First, Montana specialty pharmacies and most national specialty pharmacy networks require an active Montana-licensed prescriber on file to dispense within the state if the original prescriber is not licensed in Montana. Second, the specialty pharmacy managing the patient's existing inclisiran account may need a new prior authorization if the patient's insurance plan changes upon relocation.

The transfer process works most reliably when the patient schedules a new-patient telehealth visit with a Montana-licensed prescriber before the next injection is due. The new prescriber reviews the prior treatment record, confirms ongoing eligibility, and writes a fresh prescription in Montana. The prior lipid panel and prior-authorization history from the previous state can be submitted with the new PA packet to accelerate approval, as documented treatment response (typically a 50 percent LDL-C reduction) constitutes strong medical necessity evidence for continuation [2].

Montana does not require an additional waiting period or new step-therapy trial when a patient is continuing an established inclisiran regimen. Continuity-of-care provisions in Montana Medicaid administrative rules do not apply here since Medicaid does not cover the drug, but most commercial plans accept continuation documentation and waive repeat step-therapy requirements for established patients [9].

Dosing Schedule and Long-Term Follow-Up in Montana

Inclisiran's twice-yearly maintenance dosing schedule is one of its most practical features for Montana's rural geography. After the loading phase (injection at day 1 and day 90), patients receive a single 284 mg subcutaneous injection every 6 months [1]. Compare that to the every-2-week or every-4-week schedules for evolocumab (Repatha) and alirocumab (Praluent), which require either self-injection at home or far more frequent clinic visits [12].

For a patient in a remote Montana county, that translates to two clinic visits per year for the maintenance injections plus one or two lipid panel checks. The ACC/AHA guideline recommends checking a fasting lipid panel 4 to 12 weeks after initiating or adjusting PCSK9-pathway therapy to assess response [3]. In ORION-10, the LDL-C reduction at day 510 was sustained without dose escalation, confirming that the 284 mg fixed dose produces durable efficacy without titration [2].

Injection-site reactions occurred in 2.6 percent of inclisiran-treated patients in ORION-10 versus 1.8 percent in the placebo group and were uniformly mild [2]. No hepatotoxicity signal emerged in the pooled ORION trials, and the drug does not require routine liver-function monitoring after baseline [2, 8].

Patients should confirm their next injection appointment before leaving the clinic after each dose. A 6-month interval drifting to 7 or 8 months has not been formally studied for impact on sustained LDL-C lowering. The FDA label recommends re-dosing as close to the 6-month interval as feasible [1].

Cost, Patient Assistance, and Insurance Strategy for Montana Patients

The list price for a single Leqvio injection is approximately $3,250, making insurance coverage the deciding factor for most patients. Montana commercial plans that cover inclisiran typically list it on specialty tier, with patient cost-sharing of $100 to $500 per dose after co-pay assistance.

The Novartis Patient Assistance Foundation provides inclisiran at no cost to income-eligible patients who meet household income thresholds (generally at or below 400 percent of the Federal Poverty Level and without adequate insurance coverage). Applications are processed directly through the foundation's website, and HealthRX care coordinators can assist Montana patients in completing the paperwork.

For commercially insured patients, the Leqvio co-pay card (Novartis LEAP program) caps out-of-pocket costs at $0 per injection for eligible patients, subject to program terms [1]. This card is available to patients with private commercial insurance only, not Medicare, Medicaid, or CHIP.

Medicare Part B covers inclisiran when administered by a provider in a clinical setting, as it falls under the Medicare Part B medical benefit rather than Part D pharmacy benefit for provider-administered drugs [13]. Montana Medicare Advantage plans vary in their coverage tiers for Part B drugs; patients should verify their specific plan's coverage before scheduling the injection.

A 2023 cost-effectiveness analysis published in JAMA Cardiology found that inclisiran reaches a cost-effectiveness threshold of $100,000 per QALY at an annual price of approximately $6,500, suggesting that the current WAC price is above commonly cited thresholds for cost-effectiveness in secondary prevention populations [14]. Clinicians may cite this analysis when engaging payers in coverage appeals, noting that outcomes trials (ORION-4, ongoing, N = 15,000) will provide the definitive cardiovascular outcomes data [15].

Monitoring After the First Injection

Thirty minutes of observation after the first Leqvio injection is recommended by the FDA label to detect rare injection-site or hypersensitivity reactions [1]. Subsequent injections in patients who tolerated the first dose well do not require extended observation, though the administering clinic should have epinephrine on hand as standard practice.

A fasting lipid panel at 4 to 6 weeks post-first-injection confirms treatment response. Patients achieving an LDL-C reduction of 40 to 55 percent are responding as expected per ORION-10 data [2]. A reduction below 30 percent should prompt a medication adherence review and a reassessment of whether the injection was administered correctly (subcutaneous, not intradermal or intramuscular) [1].

Statin therapy should continue alongside inclisiran unless documented intolerance exists. The ORION trials enrolled patients already on statins, and the 50 percent incremental LDL-C reduction was measured on top of background statin therapy [2]. Discontinuing the statin while starting inclisiran would likely reduce the absolute LDL-C benefit.

Follow-up lipid panels every 6 to 12 months during maintenance are consistent with ACC/AHA monitoring recommendations for patients on PCSK9-pathway therapies [3].